# Study of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic Regimens

> **NCT01721759** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 117 (actual)

## Conditions studied

- Squamous Cell Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT01721759
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11-16
- **Primary completion:** 2014-01-22
- **Final completion:** 2021-04-22
- **Target enrollment:** 117 (ACTUAL)
- **Last updated:** 2022-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01721759

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01721759, "Study of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic Regimens". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT01721759. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*